NCT05170399View on ClinicalTrials.gov

Vaccine Responses in Patients With B Cell Malignancies

PHASE4RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

August 16, 2026

Study Completion Date

August 16, 2026

Conditions
Lymphoma
Interventions
BIOLOGICAL

Fluzone

Annual Influenza Vaccine

BIOLOGICAL

Shingrix

Recombinant, adjuvanted Zoster Vaccine (RZV)

BIOLOGICAL

Flucelvax

Annual Influenza Vaccine

BIOLOGICAL

Afluria

Annual Influenza Vaccine

BIOLOGICAL

PREVNAR 13

Pneumococcal Conjugate Vaccine (PCV13)

BIOLOGICAL

Heplisav -B

Recombinant, adjuvanted Hepatitis (HepB-CpG)

BIOLOGICAL

Pfizer-COVID-19 Vaccine

COVID-19 Vaccine

BIOLOGICAL

FluLaval

Annual Influenza Vaccine

BIOLOGICAL

Fluarix

Annual Influenza Vaccine

BIOLOGICAL

PNEUMOVAX 23

Pneumococcal Polysaccharide Vaccine (PPSV23)

DRUG

PREVNAR 20

Pneumococcal 20-Valent Conjugate Vaccine (PCV20)

DRUG

AREXVY, ABRYSVO

Respiratory Syncytial Virus Vaccine

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH